{"id":"W2193716145","doi":"10.1016/s1470-2045(15)00464-7","title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":849,"is_retracted":false,"has_abstract":false,"ca_institutions":"Western University; London Health Sciences Centre","funders":"Cilag; Onyx Pharmaceuticals; Amgen; Takeda Oncology; Spectrum Pharmaceuticals; Array BioPharma; Janssen Pharmaceuticals; Genentech; Celgene; Sanofi; Bristol-Myers Squibb; Chugai Pharmaceutical","keywords":"Carfilzomib; Medicine; Bortezomib; Dexamethasone; Multiple myeloma; Clinical endpoint; Internal medicine; Refractory (planetary science); Population; Tolerability; Interim analysis; Oncology; Surgery; Clinical trial; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002791215,0.002176891,0.003897764,0.0005564123,0.0005658571,0.001540889,0.00114855,0.002531665,0.006898107],"category_scores_gemma":[0.002563141,0.001014983,0.003129876,0.0007061108,0.002049039,0.0017519,0.0006779901,0.00373368,0.001060344],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001308133,"about_ca_system_score_gemma":0.001352547,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00211373,"about_ca_topic_score_gemma":0.003785914,"domain_scores_codex":[0.9988343,0.0006613501,0.00005904277,0.000175874,0.00007716618,0.0001922806],"domain_scores_gemma":[0.9981672,0.0006943588,0.000333605,0.000153105,0.00008640549,0.0005653087],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9908525,0.002834152,0.0002459292,0.0001965723,0.000475571,0.00001395591,0.00002940704,0.0001669185,0.0008068974,0.00004913258,0.0002442997,0.00408476],"study_design_scores_gemma":[0.9452491,0.05287846,0.0009179775,0.00001418656,0.0002935567,0.00001438982,0.00001954676,0.0001508738,0.00009891058,0.0000790531,0.0002723785,0.0000115485],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9892279,0.004348198,0.0004488696,0.000880453,0.0006727825,0.001995433,0.0008623562,0.00008159514,0.001482406],"genre_scores_gemma":[0.9889577,0.002544512,0.00113768,0.00125639,0.0007229033,0.002025351,0.000939247,0.00002193026,0.002394316],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006898107,"threshold_uncertainty_score":0.02307647,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1799697924150374,"score_gpt":0.430217007053223,"score_spread":0.2502472146381857,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}